A Mendelian randomization study for drug repurposing reveals bezafibrate and fenofibric acid as potential osteoporosis treatments

A Mendelian randomization study for drug repurposing reveals bezafibrate and fenofibric acid as potential osteoporosis treatments

Background: Lipid pathways have been implicated in the pathogenesis of osteoporosis (OP). Lipid-lowering drugs may be used to prevent and treat OP. However, the causal interpretation of results from traditional observational designs is controversial by confounding. We aimed to investigate the causal...

Full description

Bibliographic Details
Main Authors: Xiao-Hua Li, Wei-Wei Pang, Yue Zhang, Dan-Yang Liu, Qiao-Rong Yi, Ning Wang, Fu-Rong Zhang, Yun Deng, Xiang-Ding Chen, Jonathan Greenbaum, Hong-Mei Xiao, Hong-Wen Deng, Li-Jun Tan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Pharmacology
Subjects:
osteoporosis
Mendelian randomization
drug repurposing
lipid-lowering drugs
bezafibrate and fenofibric acid
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1211302/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1211302/full

Similar Items